Get the Stockscreener App
8.27
3.12%
0.25
After Hours:
8.23
-0.04
-0.48%
Quoin Pharmaceuticals Ltd Adr stock is traded at $8.27, with a volume of 7,931.
It is up +3.12% in the last 24 hours and down -29.42% over the past month.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
See More
Previous Close:
$8.02
Open:
$7.96
24h Volume:
7,931
Relative Volume:
0.02
Market Cap:
$13.37M
Revenue:
-
Net Income/Loss:
$-12.25M
P/E Ratio:
-0.0178
EPS:
-463.5156
Net Cash Flow:
$-10.77M
1W Performance:
+5.75%
1M Performance:
-29.42%
6M Performance:
+15.18%
1Y Performance:
-25.93%
1-Day Range:
$7.885
$8.27
1-Week Range:
$7.00
$8.27
52-Week Range:
$5.01
$41.80
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Company Profile
Name
Quoin Pharmaceuticals Ltd Adr
Sector
Industry
Phone
97299741444
Address
23 HATA'AS STREET, KFAR SABA
Compare QNRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNRX
Quoin Pharmaceuticals Ltd Adr
|
8.27 | 12.96M | 0 | -12.25M | -10.77M | -463.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Latest News
This Quoin Pharmaceuticals Insider Increased Their Holding By 1,515,200% Last Year - Sahm
Quoin seeks orphan drug status in Japan for Netherton Syndrome therapy By Investing.com - Investing.com India
Quoin seeks orphan drug status in Japan for Netherton Syndrome therapy - Investing.com
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome - Sahm
Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome - ChartMill
ETFs Investing in Quoin Pharmaceuticals. Ltd Sponsored ADR Stocks - TradingView — Track All Markets
Quoin Pharmaceuticals Ltd – ADR trading resumes - MSN
Quoin Pharmaceuticals (NASDAQ:QNRX) Shares Up 24.5% – Still a Buy? - Defense World
Pre Market Movers: PRAX, SPRC, QNRX Set The Pace - RTTNews
Wall Street analysts’ outlook for Quoin Pharmaceuticals Ltd ADR (QNRX) - setenews.com
US Stocks Mixed; Sea Shares Gain After Q3 ResultsMSP Recovery (NASDAQ:MSPR), Outset Medical (NASDAQ:OM) - Benzinga
Quoin Pharmaceuticals stock soars after achieving target rapamycin loadings - Investing.com
Quoin Pharmaceuticals stock soars after achieving target rapamycin loadings By Investing.com - Investing.com Philippines
Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results - Sahm
Zoetis (NYSE:ZTS) & Quoin Pharmaceuticals (NASDAQ:QNRX) Head to Head Survey - Defense World
Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - The Manila Times
Quoin Pharmaceuticals stock rises after positive pediatric trial data - Investing.com
Quoin Pharmaceuticals Ltd – ADR trading halted, volatility trading pause - MSN
Quoin Pharmaceuticals stock rises after positive pediatric trial data By Investing.com - Investing.com UK
Quoin Pharmaceuticals announces FDA granted ODD to QRX003 - TipRanks
Quoin Pharmaceuticals director Langer buys $128,640 in ADSs - Investing.com
Quoin Pharmaceuticals, Ltd.American Depositary Shares (Nasdaq:QNRX) Stock Quote | Pittsburgh Post-Gazette - FinancialContent
Quoin Pharmaceuticals (NASDAQ:QNRX) Receives Sell (E) Rating from Weiss Ratings - Defense World
Pre Market Movers: NBTX, IMTX, QNRX See Big Swings - RTTNews
Why NioCorp Developments Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - inkl
Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next? - ts2.tech
Quoin Pharmaceuticals (QNRX) Stock Is Skyrocketing Friday: What's Going On? - Benzinga
Quoin Pharmaceuticals stock soars after securing premium-priced funding - Investing.com
Quoin Pharmaceuticals secures up to $104.5 million in private placement - Investing.com
Why New Fortress Energy Shares Are Trading Higher By 41%; Here Are 20 Stocks Moving Premarket - Sahm
Quoin Pharmaceuticals. Ltd Sponsored ADR Financial Disclosures & SEC Filings - TradingView
Quoin Pharmaceuticals finalizes separation agreement with former CFO - Investing.com
Quoin Pharmaceuticals (NASDAQ:QNRX) Shares Up 2.8% – Still a Buy? - Defense World
Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Quoin Pharmaceuticals (QNRX) and RegenXBio (RGNX) - The Globe and Mail
Quoin Pharmaceuticals advances rare disease pipeline with two active trials - Investing.com
Quoin Pharmaceuticals (QNRX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Quoin Pharmaceuticals CFO Gordon Dunn to depart following mutual agreement - Investing.com
Quoin Pharmaceuticals receives FDA rare pediatric disease designation for QRX003 - Investing.com
Why Quoin Pharmaceuticals (QNRX) Stock Is Exploding Higher Wednesday - Benzinga
Quoin Pharmaceuticals regains Nasdaq compliance with bid price - Investing.com
Quoin Pharmaceuticals Ltd Share Price ADR EACH REPR 35 ORD SPON - Hargreaves Lansdown
QNRX Stock Plummets to 52-Week Low of $0.17 Amid Market Struggles - Investing.com
Quoin Pharmaceuticals announces ADS ratio change to meet Nasdaq requirements - Investing.com
Quoin Pharmaceuticals reports positive clinical data for rare disease treatment - Investing.com
QNRX Stock Plummets to 52-Week Low at $0.26 Amid Market Struggles - Investing.com
Quoin reports positive results in Netherton Syndrome study - Investing.com
Quoin Pharmaceuticals CEO Michael Myers acquires $250,000 in shares - Investing.com
Quoin Pharmaceuticals granted extension to meet Nasdaq listing - Investing.com
Quoin Pharmaceuticals COO acquires $28,737 in company shares - Investing.com India
Quoin Pharmaceuticals (QNRX) Stock Trends and Sentiment 2025 - MarketBeat
Quoin Pharmaceuticals (QNRX) Stock Forecast and Price Target 2026 - MarketBeat
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):